This provider's $3.3M in total Medicare payments ranks in the 96th percentile of Medical Oncology providers nationally.
This provider's billing patterns fall within normal ranges for their specialty.
AI-generated analysis based on Medicare payment data.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $179.03 | $94.77 | 1.89x | $84.26 | $428.2K | 12.2K | 2.5K |
| 2015 | $170.77 | $85.46 | 2.00x | $85.31 | $371.0K | 13.2K | 2.7K |
| 2016 | $194.45 | $108.03 | 1.80x | $86.42 | $338.8K | 10.9K | 2.4K |
| 2017 | $81.75 | $35.35 | 2.31x | $46.40 | $293.5K | 11.0K | 2.4K |
| 2018 | $111.12 | $52.00 | 2.14x | $59.12 | $314.8K | 11.1K | 2.6K |
| 2019 | $76.05 | $32.21 | 2.36x | $43.84 | $286.9K | 11.2K | 2.9K |
| 2020 | $71.96 | $33.01 | 2.18x | $38.95 | $277.7K | 9.9K | 2.5K |
| 2021 | $92.74 | $40.25 | 2.30x | $52.49 | $328.2K | 10.5K | 2.6K |
| 2022 | $86.56 | $36.14 | 2.40x | $50.42 | $310.0K | 10.3K | 2.9K |
| 2023 | $103.69 | $31.95 | 3.25x | $71.74 | $362.4K | 11.9K | 3.2K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | 8.6K | $770.2K | $89.54 | 1.88x |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | 4.3K | $498.7K | $116.07 | 2.84x |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | 2.4K | $302.0K | $124.47 | 1.69x |
| J2505 | Injection, pegfilgrastim, 6 mg | 89 | $235.6K | $2.6K | 1.65x |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | 3.8K | $229.6K | $60.24 | 1.91x |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | 23.8K | $215.1K | $9.03 | 2.88x |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | 3.2K | $186.6K | $58.19 | 2.25x |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | 5.9K | $93.1K | $15.80 | 2.54x |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | 528 | $89.5K | $169.48 | 1.75x |
| 36415 | Insertion of needle into vein for collection of blood sample | 25.5K | $87.7K | $3.44 | 5.22x |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | 3.3K | $84.1K | $25.73 | 2.72x |
| 96360 | Hydration infusion into a vein 31 minutes to 1 hour | 1.9K | $75.0K | $38.88 | 2.68x |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | 1.1K | $66.4K | $63.12 | 1.64x |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | 999 | $55.5K | $55.55 | 2.79x |
| 96374 | Injection of drug or substance into a vein for therapy, diagnosis, or prevention | 1.3K | $54.4K | $41.59 | 2.35x |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | 397 | $51.7K | $130.22 | 1.81x |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | 2.1K | $33.0K | $15.88 | 2.87x |
| J9310 | Injection, rituximab, 100 mg | 36 | $25.5K | $707.28 | 1.59x |
| J9041 | Injection, bortezomib, 0.1 mg | 614 | $22.0K | $35.89 | 2.12x |
| J2469 | Injection, palonosetron hcl, 25 mcg | 1.3K | $13.8K | $10.78 | 4.40x |
This provider submits charges 2.35 times higher than what Medicare actually pays.
A markup ratio of 2.35x means for every $100 Medicare pays, this provider initially charges $235. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data